Phillips Medisize 达成协议扩建英国吸入制剂产能,完成 Chippenham 基地整体布局
Phillips Medisize strikes deal to expand UK inhalation production
Phillips Medisize 达成协议完成其英国 Chippenham 基地的整体布局,该基地将与剑桥基地共同强化其全球吸入制剂卓越中心并扩大产能。该基地面积 634,670 平方英尺、占地 3.41 英亩,将支持药物-器械组合产品处方开发及早期和后期临床试验用品生产。交易财务条款未披露,公司称未来五年吸入制剂收入预计大幅增长。

Phillips Medisize, a Molex subsidiary CDMO that focuses on inhalation products and other medical and diagnostic products, is expanding its manufacturing footprint in the U.K. (iStock/Getty Images Plus)
Phillips Medisize, a Molex subsidiary CDMO that focuses on inhalation products and other medical and diagnostic products, is expanding its manufacturing footprint in the U.K.
Under the newly disclosed investment, Phillips Medisize will finish out the footprint of its Chippenham site that, together the company’s Cambridge facility, will boost its global inhalation center of excellence and expand capacity to support expected growth in the sector, the company said in a press release.
The 634,670-square-foot site that sits on 3.41 acres will support Phillips Medicine’s ambition to grow drug-device combination product formulation development for early and late-phase clinical trial supplies production.
Financial terms of the deal weren’t disclosed.
“With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories and cleanroom capacity required to support pharmaceutical companies from early-stage feasibility all the way through commercial scale-up,” Charlie Schumacher, vice president of inhalation therapies at Phillips Medisize, said in a statement. “Since the Vectura acquisition, we are tracking ahead of schedule on our growth model and are confident in our trajectory.”
Phillips Medisize acquired Vectura through Molexin late 2024 for an undisclosed price. The developer and maker of inhaled medicines and devices like asthma inhalers, nebulizers and dry-powder inhalers was previously purchased for $1.2 billion in 2021 by Philip Morris International.
Molex is a wholly-owned subsidiary of Koch (formerly Koch industries), which acquired the Illinois maker of electronic, electrical, and fiber optic connectivity systems in 2013 for an estimated $7.2 billion.
来源:Fierce Pharma Manufacturing · fiercepharma.com